Drugmakers Set to Face Off Over Obesity-Led Liver Diseases – Bloomberg



Bloomberg

Drugmakers Set to Face Off Over Obesity-Led Liver Diseases
Bloomberg
The multibillion-dollar market potential for obesity-driven liver disease has prompted biopharmaceutical companies large and small to chase after treatments. Intercept Pharmaceuticals Inc.'s Ocaliva, already prescribed for a bile-duct disorder, is seen



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.